Evaluation of satisfaction and preference in patients with osteoporosis receiving Denosumab
More Detail
1 Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Medical Faculty, Adnan Menderes University, Aydın, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 18, Issue 1, pp. 44-47.
https://doi.org/10.23950/jcmk/9654
OPEN ACCESS
1729 Views
1338 Downloads
ABSTRACT
Objective: Satisfaction and preference properties differs in osteoporosis treatment agents. In our study we aimed to evaluate these properties in patients receiving denosumab treatment.
Materials and Methods: Thirty female patients who had denosumab injections were included in our study. Demographic and general characteristics were recorded.
General patient satisfaction, patient satisfaction of the drug and it's effect on quality of life was evaluated on a Likert scale. Patients' preference was evaluated with asking the reasons of switches to denosumab.
Results: The mean age of patients was 59.30±12.86 years. Of the patients 30 (% 100.0) wanted to continue the same therapy, 25 (%83.3) patients stated that managing this treatment is extremely easy. 25 (% 83.3) patients stated that it was extremely well-suited with lifestyle.25 (% 83.3) patients were extremely convenient to take medication.25 (% 83.3) patients have extremely willed to continue to use the medication. Of 30 patients, 30(% 100) have been switched to denosumab due to physician recommendation. Physician recommended have been done to these patients due to ineffectivity of previous osteoporosis treatments or due to side effects of previous osteoporosis treatments. 22 (%73.33) of these patients have been switched to denosumab due to ineffectivity of previous osteoporosis treatments. About 8 (%26.66) patients have been switched to denosumab due to side effects of previous osteoporosis treatments.
Conclusion: Denosumab treatment in osteoporosis is a convenient and well-tolerated therapeutic modality.
CITATION
Sargın B. Evaluation of satisfaction and preference in patients with osteoporosis receiving Denosumab. J CLIN MED KAZ. 2021;18(1):44-7.
https://doi.org/10.23950/jcmk/9654
REFERENCES
- Chen SJ, Lin CS, Lin CL, Kao CH. Osteoporosis is associated with high risk for coronary heart disease: a population-based cohort study. Medicine (Baltimore). 2015; 94:e1146. https://doi.org/10.1097/MD.0000000000001146
- Kaushal N, Vohora D, K.Jalali R, Jha S. Prevalence of osteoporosis and osteopenia in an apparently healthy Indian population-a cross-sectional retrospective study. Osteoporosis and Sarcopenia. 2018; 53-60. https://doi.org/10.1016/j.afos.2018.04.002
- Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018; 14:2029-49. https://doi.org/10.2147/TCRM.S138000
- Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9:1137-41. https://doi.org/10.1002/jbmr.5650090802
- Briot K, Roux C, Thomas T, Blain H, Buchon D, Chapurlat R, et al. 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine. 2018; 85:519-30. https://doi.org/10.1016/j.jbspin.2018.02.009
- Coronado-Zarco R, Olascoaga-Gómez de León A, García-Lara A, Quinzaños-Fresnedo J, Nava-Bringas TI, Macías-Hernández SI. Nonpharmacological interventions for osteoporosis treatment: Systematic review of clinical practice guidelines. Osteoporos Sarcopenia. 2019; 5:69-77. https://doi.org/10.1016/j.afos.2019.09.005
- Kanis JA,Cooper C, Rizzoli R, Reginster JY, and on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF).European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019; 30:3-44. https://doi.org/10.1007/s00198-018-4704-5
- Polyzos SA, Makras P, Tournis S, Anastasilakis AD. Off-label uses of denosumab in metabolic bone diseases. Bone. 2019; 129:115048. https://doi.org/10.1016/j.bone.2019.115048
- Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2018; 10:209-23. https://doi.org/10.1177/1759720X18805759
- Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017; 4:46-56. https://doi.org/10.5152/eurjrheum.2016.048
- Morizio P, Burkhart JI, Ozawa S. Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients. Ann Pharmacother. 2018; 52:1031-41. https://doi.org/10.1177/1060028018768808
- Sheedy KC, Camara MI, Camacho PM. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocr Pract. 2015; 21:275-9. https://doi.org/10.4158/EP14106.OR
- Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, etal. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011; 22:1725-35. https://doi.org/10.1007/s00198-010-1378-z
- Kendler DL, Chines A, Brandi ML, Papapoulos S, Lewiecki EM, Reginster JY, et al. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies. Osteoporos Int. 2019; 30:71-8. https://doi.org/10.1007/s00198-018-4687-2
- Dempster DW,Brown JP, Fahrleitner-Pammer A,Kendler D,Rizzo S,Valter I, et al. Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018; 103:2498-509. https://doi.org/10.1210/jc.2017-02669